nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

18.10.2019 | Review

Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies

verfasst von: Longui Ning, Rongqiang Liu, Sha Li, Guodong Shan, Haojie Du, Jie Zhang, Wenguo Chen, Fenming Zhang, Jinghua Yu, Guoqiang Xu

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have shown increased risk of herpes zoster (HZ) infection in patients with inflammatory bowel disease (IBD). The aim of this study is to better characterize this possible association by conducting a meta-analysis. A comprehensive search of relevant literature until April 30, 2019, was performed. Data on HZ infection and medications in patients with IBD and controls were extracted. The relative risk (RR) and 95% confidence interval (CI) were calculated. Subgroup analyses were performed to assess the source of heterogeneity. Seven cohort studies were included that involved more than 1,000,000 participants. The RR of HZ infection in patients with Crohn’s disease (CD) compared with non-CD patients was 1.74 (95% CI 1.57–1.92, p < 0.001). The pooled RR of HZ infection in patients with ulcerative colitis (UC) compared with non-UC was 1.40 (95% CI 1.31–1.50, p < 0.001). Subgroup analyses revealed that age, race, and publication year contribute to heterogeneity. We also found that steroid users were at increased risk of HZ in CD (OR = 1.78, 95% CI 1.10–2.88). Steroid users and anti-TNFα users were at increased risk of HZ in UC, with RRs of 1.99 (95% CI 1.64–2.42) and 2.29 (95% CI 1.52–3.45), respectively. Begg’s test and Egger’s test suggested no publication bias. There was a 74% increased risk of HZ infection in patients with CD and 40% increased risk of HZ infection in patients with UC compared with that in non-IBD. IBD patients with high risk of HZ infection may benefit from an HZ vaccine.

Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI (2017) IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev 16(4):416–426. https://doi.org/10.1016/j.autrev.2017.02.013 CrossRefPubMed

Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, LeMair AW, Malfertheiner OQ, Rey JF, Sood A, Steinwurz F, Thomsen OO, Thomson A, Watermeyer G (2010) World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 16(1):112–124. https://doi.org/10.1002/ibd.21048 CrossRefPubMed

Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, Yang YX (2018) Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 16(12):1919–1927.e1913. https://doi.org/10.1016/j.cgh.2017.12.052 CrossRef

Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R (2018) Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155(2):337–346.e310. https://doi.org/10.1053/j.gastro.2018.04.012 CrossRef

Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S (2016) Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 14(10):1385–1397.e1310. https://doi.org/10.1016/j.cgh.2016.04.039 CrossRef

Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS (2007) A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82(11):1341–1349CrossRef

Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, Chang LY (2010) Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 28(5):1217–1220. https://doi.org/10.1016/j.vaccine.2009.11.029 CrossRefPubMed

Harpaz R, Ortega-Sanchez IR, Seward JF (2008) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR recommendations and reports : morbidity and mortality weekly report recommendations and reports 57(Rr-5):1–30 quiz CE32-34PubMed

Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM (2014) Quantification of risk factors for herpes zoster: population based case-control study. BMJ (Clinical research ed) 348:g2911. https://doi.org/10.1136/bmj.g2911 CrossRef

10.

Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57(8):1431–1438. https://doi.org/10.1002/art.23112 CrossRefPubMed

11.

Cote-Daigneault J, Bessissow T, Nicolae MV, Nie R, Bitton A, Lakatos PL, Brassard P (2018) Herpes zoster incidence in inflammatory bowel disease patients: a population-based study. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izy311 CrossRef

12.

Gupta G, Lautenbach E, Lewis JD (2006) Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 4(12):1483–1490. https://doi.org/10.1016/j.cgh.2006.09.019 CrossRef

13.

Long MD, Martin C, Sandler RS, Kappelman MD (2013) Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 37(4):420–429. https://doi.org/10.1111/apt.12182 CrossRefPubMed

14.

Soh H, Chun J, Han K, Park S, Choi G, Kim JH, Lee J, Im JP, Kim JS (2018) Increased risk of herpes zoster in young and metabolically healthy patients with inflammatory bowel disease: a nationwide population-based study. Gut and liver. https://doi.org/10.5009/gnl18304 CrossRef

15.

Tsai SY, Yang TY, Lin CL, Tsai YH, Kuo CF, Kao CH (2015) Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract 69(2):228–234. https://doi.org/10.1111/ijcp.12508 CrossRefPubMed

16.

Chang K, Lee HS, Kim YJ, Kim SO, Kim SH, Lee SH, Song EM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK (2018) Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 16(12):1928–1936.e1922. https://doi.org/10.1016/j.cgh.2018.05.024 CrossRef

17.

Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ (2009) Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol 104(10):2524–2533. https://doi.org/10.1038/ajg.2009.322 CrossRefPubMed

18.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z CrossRef

19.

Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET (2013) Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis. Hum Reprod Update 19(2):105–123. https://doi.org/10.1093/humupd/dms051 CrossRefPubMed

20.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557 CrossRef

21.

Khan N, Trivedi C, Kavani H, Medvedeva E, Lewis J, Yang YX (2018) Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. https://doi.org/10.1016/j.cgh.2018.10.016 CrossRef

22.

Che H, Lukas C, Morel J, Combe B (2014) Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint, bone, spine : revue du rhumatisme 81(3):215–221. https://doi.org/10.1016/j.jbspin.2013.07.009 CrossRef

23.

Marra F, Lo E, Kalashnikov V, Richardson K (2016) Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open forum infectious diseases 3(4):ofw205. https://doi.org/10.1093/ofid/ofw205 CrossRefPubMedPubMedCentral

24.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR (2013) Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. Jama 309(9):887–895. https://doi.org/10.1001/jama.2013.1099 CrossRefPubMedPubMedCentral

25.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367(7):616–624. https://doi.org/10.1056/NEJMoa1112168 CrossRefPubMed

26.

Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C (2018) Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 24(10):2258–2265. https://doi.org/10.1093/ibd/izy131 CrossRefPubMedPubMedCentral

27.

Farraye FA, Melmed GY, Lichtenstein GR, Kane SV (2017) ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 112(2):241–258. https://doi.org/10.1038/ajg.2016.537 CrossRefPubMed

28.

Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF (2014) Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8(6):443–468. https://doi.org/10.1016/j.crohns.2013.12.013 CrossRefPubMed

29.

Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR (2012) Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. Jama 308(1):43–49. https://doi.org/10.1001/jama.2012.7304 CrossRefPubMedPubMedCentral

30.

Khan N, Shah Y, Trivedi C, Lewis JD (2017) Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther 46(7):668–672. https://doi.org/10.1111/apt.14257 CrossRefPubMed

31.

Khan N, Trivedi C, Shah Y, Patel D, Lewis J, Yang YX (2018) The severity of herpes zoster in inflammatory bowel disease patients treated with anti-TNF agents. Inflamm Bowel Dis 24(6):1274–1279. https://doi.org/10.1093/ibd/izx115 CrossRefPubMed

32.

Wasan SK, Zullow S, Berg A, Cheifetz AS, Ganley-Leal L, Farraye FA (2016) Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression. Inflamm Bowel Dis 22(6):1391–1396. https://doi.org/10.1097/mib.0000000000000743 CrossRefPubMed

33.

Thomas SL, Hall AJ (2004) What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4(1):26–33CrossRef

34.

Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ (2011) Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Jama 305(2):160–166. https://doi.org/10.1001/jama.2010.1983 CrossRefPubMed

Titel: Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies
verfasst von: Longui Ning
Rongqiang Liu
Sha Li
Guodong Shan
Haojie Du
Jie Zhang
Wenguo Chen
Fenming Zhang
Jinghua Yu
Guoqiang Xu
Publikationsdatum: 18.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 2/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-019-03706-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Evaluation of Bio-Rad® discs for antimicrobial susceptibility testing by disc diffusion and the ADAGIO™ system for the automatic reading and interpretation of results

The added value of the selective SuperPolymyxin™ medium in detecting rectal carriage of Gram-negative bacteria with acquired colistin resistance in intensive care unit patients receiving selective digestive decontamination

Detection of sexually transmitted disease–causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit

Cytokine levels predict 30-day mortality in octogenarians and nonagenarians with community-acquired pneumonia: a retrospective observational study

Long-term, single-center surveillance of non-invasive group A streptococcal (GAS) infections, emm types and emm clusters